Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FBLG NASDAQ:HLVX NASDAQ:SAVA NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBLGFibroBiologics$0.58+9.0%$0.70$0.53▼$4.41$22.38M-0.74502,197 shs1.01 million shsHLVXHilleVax$2.07+0.5%$2.02$1.34▼$2.17$103.29M0.77805,548 shs112,818 shsSAVACassava Sciences$2.18-0.5%$2.13$1.15▼$33.98$105.79M-2.05852,422 shs556,509 shsZURAZura Bio$1.42-4.1%$1.32$0.97▼$5.07$101.19M-0.06873,455 shs232,648 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBLGFibroBiologics+9.02%-10.21%-11.76%-29.88%-84.39%HLVXHilleVax+0.49%+1.47%-2.36%+8.95%+28.57%SAVACassava Sciences-0.46%+2.83%-0.46%+23.16%-92.78%ZURAZura Bio-4.05%-5.33%+5.19%+17.36%-59.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFBLGFibroBiologics3.2667 of 5 stars3.64.00.00.02.42.50.6HLVXHilleVax1.7417 of 5 stars1.05.00.00.01.83.31.3SAVACassava Sciences2.3464 of 5 stars1.03.00.04.71.30.01.3ZURAZura Bio3.7158 of 5 stars3.65.00.00.03.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFBLGFibroBiologics 3.20Buy$13.002,132.14% UpsideHLVXHilleVax 2.00Hold$2.00-3.38% DownsideSAVACassava Sciences 2.00Hold$2.00-8.26% DownsideZURAZura Bio 3.13Buy$14.33909.39% UpsideCurrent Analyst Ratings BreakdownLatest FBLG, ZURA, SAVA, and HLVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025FBLGFibroBiologicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $12.008/4/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.007/29/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.007/9/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/17/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/15/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/9/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.00(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFBLGFibroBiologicsN/AN/AN/AN/A$0.02 per shareN/AHLVXHilleVaxN/AN/AN/AN/A$2.95 per shareN/ASAVACassava SciencesN/AN/AN/AN/A$3.03 per shareN/AZURAZura BioN/AN/AN/AN/A$2.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFBLGFibroBiologics-$11.16M-$0.36N/AN/AN/AN/A-710.25%-118.02%N/AHLVXHilleVax-$147.27M-$1.43N/AN/AN/AN/A-34.29%-28.50%8/14/2025 (Estimated)SAVACassava Sciences-$24.34M-$1.50N/AN/AN/AN/A-87.72%-72.05%8/14/2025 (Estimated)ZURAZura Bio-$45.39M-$0.70N/AN/AN/AN/A-42.84%-35.22%8/12/2025 (Estimated)Latest FBLG, ZURA, SAVA, and HLVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025HLVXHilleVax-$0.14N/AN/AN/AN/AN/A8/12/2025Q2 2025ZURAZura Bio-$0.19N/AN/AN/AN/AN/A8/6/2025Q2 2025HLVXHilleVax-$0.14-$0.11+$0.03-$0.11N/AN/A7/31/2025Q1 2025FBLGFibroBiologics-$0.11-$0.12-$0.01-$0.12N/AN/A5/13/2025Q1 2025FBLGFibroBiologics-$0.10-$0.14-$0.04-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFBLGFibroBiologicsN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFBLGFibroBiologicsN/A0.930.93HLVXHilleVaxN/A26.3925.32SAVACassava SciencesN/A9.089.08ZURAZura BioN/A8.148.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFBLGFibroBiologicsN/AHLVXHilleVax86.42%SAVACassava Sciences38.05%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipFBLGFibroBiologics20.00%HLVXHilleVax24.90%SAVACassava Sciences2.40%ZURAZura Bio14.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFBLGFibroBiologics1041.89 million33.51 millionN/AHLVXHilleVax2050.14 million37.66 millionNot OptionableSAVACassava Sciences3048.31 million47.15 millionOptionableZURAZura Bio368.38 million58.65 millionOptionableFBLG, ZURA, SAVA, and HLVX HeadlinesRecent News About These CompaniesZura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from BrokeragesAugust 7 at 3:54 AM | marketbeat.comZura Bio (ZURA) Projected to Post Quarterly Earnings on TuesdayAugust 6 at 10:28 AM | marketbeat.comZura Bio (NASDAQ:ZURA) Shares Up 7.5% - What's Next?August 6 at 4:26 AM | marketbeat.comRobert Lisicki on Living Up to Zura Bio’s Heroic NamesakeJuly 31, 2025 | pharmexec.comP3 Penny Stocks With Market Caps Over $70M Worth WatchingJuly 18, 2025 | finance.yahoo.comZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 | finance.yahoo.comZura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of "Buy" by AnalystsJuly 13, 2025 | marketbeat.comZura Bio (NASDAQ:ZURA) Trading 12.5% Higher - Here's What HappenedJuly 10, 2025 | marketbeat.comZura Bio Announces Chief Financial Officer TransitionJuly 1, 2025 | businesswire.comZura Bio shareholders approve board nominees and auditorMay 24, 2025 | investing.comZura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativaMay 21, 2025 | msn.comZura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis SuppurativaMay 20, 2025 | businesswire.comZura Bio Reports First Quarter 2025 Financial Results and Recent Corporate UpdatesMay 9, 2025 | standard-journal.comSAfter losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gainApril 24, 2025 | finance.yahoo.comZura Bio price target lowered to $3 from $5 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comZura Bio (ZURA) Gets a Buy from GuggenheimMarch 31, 2025 | markets.businessinsider.comHopeful Week For Insiders Who Bought US$1.01m Of Zura Bio StockMarch 26, 2025 | finance.yahoo.comZura Bio Limited: 2024 Financial Results and Strategic ProgressMarch 25, 2025 | tipranks.comZura Bio Reports Full Year 2024 Financial Results and Recent Corporate UpdatesMarch 25, 2025 | businesswire.comZura Bio to Present at the Leerink Partners Global Healthcare ConferenceFebruary 24, 2025 | businesswire.comZURA stock touches 52-week low at $1.44 amid market shiftsFebruary 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBLG, ZURA, SAVA, and HLVX Company DescriptionsFibroBiologics NASDAQ:FBLG$0.58 +0.05 (+9.02%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.58 -0.01 (-1.10%) As of 08/8/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.HilleVax NASDAQ:HLVX$2.07 +0.01 (+0.49%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.06 0.00 (-0.24%) As of 08/8/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Cassava Sciences NASDAQ:SAVA$2.18 -0.01 (-0.46%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.24 +0.05 (+2.52%) As of 08/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Zura Bio NASDAQ:ZURA$1.42 -0.06 (-4.05%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.44 +0.03 (+1.76%) As of 08/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
